NCT04033328 - Study of ORIC-101 in Combination With Enzalutamide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

November 22, 2022

Study Completion Date

December 4, 2023

Conditions

Prostatic Neoplasms

Interventions

DRUG

ORIC-101

ORIC-101 once daily in each 28-day cycle

DRUG

enzalutamide 40 MG oral capsule [Xtandi]

160 mg once daily in each 28-day cycle

Trial Locations (3)

Memorial Sloan Kettering Cancer Center, New York

Carolina Urologic Research Center, Myrtle Beach

MD Anderson Cancer Center, Houston